The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...